Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
07:40 - 08:40

Registration

More
Showing of Streams
10:45 - 11:10

Morning Coffee and Networking

More
Showing of Streams
12:55 - 14:10

Lunch, Networking and Live Labs

More
Showing of Streams
16:00 - 16:30

Afternoon Coffee

More
Showing of Streams
17:40 - 17:50

Time to move into Plenary Session

More
17:50 - 18:10
Info

Rapid Quantification of Adeno-Associated Virus and Lentivirus Vectors

Viral vectors such as adeno-associated virus (AAV) and lentivirus are currently in use for gene and cell therapies.  Rapid and accurate enumeration of these viral particles is critical for the safety and efficacy of these promising new therapies.  However, obtaining this information can be a challenge as current techniques are slow and imprecise.   ELISA tests are subjective and the variability depends on the operator.  qPCR takes hours and ultimately only delivers a genome count.  While vector genomes/mL is required for dosing, further characterization of the vector formulations is required for patient safety.  Furthermore, the amount of time involved in these methods makes them challenging for use in in-process monitoring of vector growth and formulation.  The Virus Counter 3100® platform using antibody-based ViroTag® reagents from Sartorius Virus Analytics offers a rapid and precise solution to these problems. 

Here, we show how the ViroTag AAV2-3 and ViroTag VSV-G can be used to quantify crude and purified AAV-2, AAV-3, and VSV-G pseudo-typed lentivirus vectors.  Using a patented no-wash assay and the Virus Counter 3100 platform, biologically relevant total particle counts can be obtained in three minutes following a 30 minute incubation.   The speed and precision of this technique makes it practical for in-process monitoring as well as characterization of a final formulation.

  • Rebecca Montange - Scientist, Sartorius Stedim North America, Inc, USA
More
18:10 - 18:30
Info

Gene Therapy Center Austria: High quality AAV solutions for clinical and commercial supply.

FDA expects to approve 40 gene therapies by 2022, a significant number is based on AAV. As of today PhI/II AAV capacities are installed at product companies and CMOs but no set-ups are available to support industries GT ambitions.

The Gene Therapy Center Austria (GTCA) proprietary AAV platform covers all steps from vector to product including a broad range of analytical methods. 40+ GMP lots have already been released out of our state-of-the-art Gene Therapy plant specifically designed for AAV processes, demonstrating lot-to-lot consistency and process robustness across AAV subtypes. Our partners benefit from our 30+ years’ experience in late stage development and global commercialization of recombinant proteins and vaccines.

  • Larissa Kahr - Head of Gene Therapy Strategy & Business Development Process Development & Technical Services, Shire, Austria
More
18:30 - 20:30

Networking Drinks and Evening Social Event

More
07:40 - 08:40 60 mins
Registration
08:40 - 08:45 5 mins
Joint Plenary Session
Chairperson’s Opening remarks
  • Miguel Forte - CEO, Zelluna, Norway
08:45 - 09:05 20 mins
Info
Joint Plenary Session
Innovative solutions from Industry 4.0
  • Michael May - President and CEO, CCRM, Centre For Commercialization Of Regenerative Medicine
  • Potential to providing real-time visibility 
  • Control across complex cell and gene therapy supply chains 
  • QbD
  • How can industry 4.0 drive the industry towards increased industrialization?
09:05 - 09:25 20 mins
Info
Joint Plenary Session
Designing production facilities of the future
  • Geoffrey Hodge - Chief Technical Officer, Unum Therapeutics, USA
  • Case study
  • How can facilities be produced to meet the potential demand of cell and viral vectors
  • What needs to change and what innovations are being made
09:25 - 09:45 20 mins
Info
Joint Plenary Session
Patient specific therapies and the need for a paradigm shift
  • Ohad Karnieli - CEO & Co-Founder, Atvio, Israel
  • How innovation could lead to a more flexible process based on having enhanced product and process understanding
  • How would this then be adaptable to manage critical sources of variability
  • Potential for Analytical Technologies (PAT) comprised of sensors with multivariate data analytics and control algorithms as well as electronic data records and enterprise systems to enable efficient knowledge sharing across components in the supply chain
09:45 - 10:05 20 mins
Info
Joint Plenary Session
Industrializing Cell Therapies: Managing Complexity Across the Ecosystem
  • Philip G. Vanek, Ph.D - GM, Cell and Gene Therapy Strategy, GE Healthcare

Cell and gene therapies are quickly reaching an inflection point, changing forever how we think about treating patients. Despite the exceptional therapeutic promise, there remain significant challenges to be addressed before routine clinical adoption. The cell and gene therapy ecosystem - encompassing biology, manufacturing, and logistics - continues to be stretched to meet the rapidly evolving needs of this industry. Both solution providers and therapy manufacturers are trying to balance the need to simplify and de-risk their processes, while maintaining flexibility to adapt to a variety of cell types, genetic manipulations, and dosing volumes. Manufacturers also need to consider optimizing labor, equipment, and clean-room space as patient numbers increase, including when to integrate digital solutions to provide decision support. This talk will discuss how the interplay of these elements can be managed to assure safe, scalable, and reproducible access to these therapies.

10:05 - 10:20 15 mins
Info
Joint Plenary Session
The road to commercialization: development of cGMP compliant cell and gene therapy process from concept to patient
  • Behnam Ahmadian Baghbaderani, PhD - Global Head of Process Development, Emerging Technologies, Lonza

Production of high quality Cell and Gene Therapy (C&GT) products is fundamentally dependent on the design and development of manufacturing processes according to current Good Manufacturing Practices (cGMP). Here we highlight some of the key challenges in the development of cGMP compliant and commercially viable processes for C&GT applications including the use of open, manual, and uncontrolled 2D cell culture system and unit operations. We then underline our approach towards addressing these challenges by (1) applying best process optimization practices to establish a robust and reproducible manufacturing process, and (2) implementing innovative, automated, scalable, closed, bioreactor system in the process.

10:20 - 10:45 25 mins
Info
Joint Plenary Session
Discussion Panel: What do industry need to innovate the cell and viral vector industries?
  • Ohad Karnieli - CEO & Co-Founder, Atvio, Israel
  • Michael May - President and CEO, CCRM, Centre For Commercialization Of Regenerative Medicine
  • Geoffrey Hodge - Chief Technical Officer, Unum Therapeutics, USA
  • Jean - Yves Lombard - Business Manager, Bioprocessing Solutions, Saint-Gobain, France
  • Francesca Bellintani - Downstream Vector Process Development Manager, MolMed, Italy
  • Fernanda Masri - Technology Expert for Regenerative Medicine, Sartorius Stedim, UK
  • What innovations do industry need to make it possible to treat 100’s of patients? 
  • What can vendors do to innovate platforms they currently provide?
  • Where do the gap’s lie?
  • What is can be done to prevent demand outgrowing capacity?
10:45 - 11:10 25 mins
Morning Coffee and Networking
11:10 - 11:15 5 mins
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Chairperson's Opening Remarks
  • Tristan Thwaites - Lead Technical Scientist, Cell and Gene Therapy, Catapult
11:10 - 11:15 5 mins
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Chairperson's Opening Remarks
  • Francesco Cicirello - Chairperson PIC/S Working Group on Annex 2 Revision, Inspector, Australia
11:15 - 11:50 35 mins
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Advanced spectroscopic techniques for real time process characterisation
  • John Churchwell - Senior Scientist – Analytical Development, Cell and Gene Therapy Catapult
11:15 - 11:50 35 mins
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Zelluna Immunotherapy Case Study
  • Arjan Roozen - CTO, Zelluna, Norway
11:45 - 11:50 5 mins
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
Chairperson's Opening Remarks
  • Lior Raviv - Vice President of Development, Pluristem
11:50 - 12:25 35 mins
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Case study: Equivalence testing for a multi-plate potency assay of viral vector
  • Sara Paulo - Senior Analytical Specialist, FinVector Oy, Finland
11:50 - 12:25 35 mins
Info
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
Implementation of an affordable and scalable manufacturing strategy
  • Bas Leewis - MSAT Manager, MeriaGTx, UK
  • Case study
11:50 - 12:25 35 mins
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Gamma-Delta T Cell Case Study
  • Michael Leek - CEO, TC BioPharm, UK
12:25 - 12:55 30 mins
Info
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Manufacturing of API-grade lentiviral vectors – what`s behind quality?
  • Tanno Hübel - Head of Production for biological GMP products, Miltenyi Biotec GmbH

Lentiviral vectors for manufacturing of CAR-T cells as drug product are active pharmaceutical ingredients (API), at least in Germany. Manufacturing authorization for lentiviral vectors is required. Manufacturing of lentiviral vectors in an animal-component free, 200-L process was inspected by the local authority and authorizations were granted. Safety aspects such as viral and other process related contaminations, replication competent lentiviruses, identity, and functionality have to be addressed carefully. On the other hand quality aspects such as robust transduction efficiencies and functional expression of the antigen receptor in the target cells has to be considered. Impact of the manufacturing process on the quality of lentiviral vectors and regulatory requirements will be discussed.

12:25 - 12:55 30 mins
Info
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
Viral Safety in Viral Therapeutics
  • Rolf Werner - Chairman Scientific Board, Labor Dr. Merk & Kollegen, Germany
  • Advanced Therapeutic Medical Products (ATMP)
  • Adherent and suspension cell processes for viral production
  • Preventive viral safety measures
  • Affinity chromatography for ATMP
  • Mini TEM for adventitious viral contaminants

Advanced Therapeutic Medical Products (ATMP) are emerging to the clinic and market. Historically a  number of host cells for propagation of viral vectors such as adenovirus, adeno associated virus, lentivirus, MVA, retrovirus, vaccinia virus, vesicular stomatitis virus, parapox virus are adherent cell cultures such as BGM-, MDCK-, MRC- and Vero-cells, growing in FBS, with a potential safety risk of contaminations with adventitious viruses. Alternatively adherent cells can be adapted to growth in suspension, or more smart viral vectors are propagated directly in suspension cells such as HEK 293-, CAP- or HeLa cells. These cells can be grown in serum free, chemically defined media, avoiding potential contaminations with adventitious viruses. Scale up is straight forward in a 1:5 ratio up to 4,000L SUB, sufficient for clinical and commercial supply.

Since the viral therapeutics are sensitive to all conventional viral inactivation and removal steps, preventive measures have to be applied to guarantee viral safety of contaminating adventitious viruses. MVB/WVB and MCB/WCB absolutely free of adventitious viruses. Fermentation operated in serum free and chemically defined media in a closed system. Resins, membranes are sanitisized, media and buffers have to be nano-filtered. Affinity chromatography to capture specifically the viral therapeutic. A qualified spectrum of analytical methods has to address purity, empty and full capsides, aggregates, HCP, HCD and adventitious viruses (Mini TEM). The plant should be operated under BSL 2-3 at cGMP in Class C and Class A for fill & finish in adequate scale for clinical and commercial material. Labor Dr. Merk & Kollegen, Germany can provide such services in a one stop shop.

12:25 - 12:55 30 mins
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Overcoming Challenges in Viral Vector and Vaccine Manufacture
  • Daniel DeVido - Director, Strategic Business Development, Fujifilm Diosynth Biotechnologies
12:55 - 14:10 75 mins
Lunch, Networking and Live Labs
14:10 - 14:45 35 mins
Info
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Combination of analytical methods for characterization of viral vectors
  • Katy Barglow - VP, Process and Analytical Development, 4D Molecular Therapeutics, USA
  • Analytical methods used in development and production of vectors for gene therapy
  • Quantification with molecular methods
  • Need for standards in analytical methods for vectors
14:10 - 14:45 35 mins
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
Case study: Use of stir tank bioreactor and BEVS technology to produce at 500L scale
  • Juan Pablo Labbrozzi - Lead Scientist, UniQure Biopharma BV, Netherlands
14:10 - 14:45 35 mins
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Celyad Case Study
  • Peggy Sotiropoulou - Director Research & Development, Celyad, Belgium
14:45 - 15:20 35 mins
Info
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Panel discussion: What can cell therapy manufacturers learn from MAbs to save time and money on the path to commercial scale manufacturing
  • Moderator Christopher Bravery - Director, Training Courses Department, Consulting On Advanced Biologicals Ltd
  • Panellist Karin Hoogendoorn - Scientist ATMP Product Development, Leiden University Medical Centre (LUMC), The Netherlands
  • Panelist Greg Stromberg - Associate Director, Global Manufacturing Sciences, Biogen, USA
  • Panelist Houssam Alosta - Senior Manager, Bioprocess Engineering, BlueRock Therapeutics, Canada
  • Benoit Champluvier - Chief Technology and Manufacturing Officer, Bone Therapeutics, Belgium


  • Where current gaps lie in cell therapy manufacturing – do MAb manufacturers have advice on how to fill these
  • What technologies and process improvements can the cell therapy industry take away from their counterparts
  • Feedback and discussion on how to improve current processes
14:45 - 15:20 35 mins
Info
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
Panel discussion: What can cell therapy manufacturers learn from MAbs to save time and money on the path to commercial scale manufacturing
  • Moderator Christopher Bravery - Director, Training Courses Department, Consulting On Advanced Biologicals Ltd
  • Panellist Karin Hoogendoorn - Scientist ATMP Product Development, Leiden University Medical Centre (LUMC), The Netherlands
  • Panelist Greg Stromberg - Associate Director, Global Manufacturing Sciences, Biogen, USA
  • Panelist Houssam Alosta - Senior Manager, Bioprocess Engineering, BlueRock Therapeutics, Canada
  • Benoit Champluvier - Chief Technology and Manufacturing Officer, Bone Therapeutics, Belgium


  • Where current gaps lie in cell therapy manufacturing – do MAb manufacturers have advice on how to fill these
  • What technologies and process improvements can the cell therapy industry take away from their counterparts
  • Feedback and discussion on how to improve current processes
14:45 - 15:20 35 mins
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Case study: ART-I02, a gene therapy vector for arthritis
  • Janneke Meulenberg - COO, Arthrogen, Netherlands
15:20 - 15:40 20 mins
Info
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Modelling the Costs of Process Scale-Up of AAV for Gene Therapy
  • Clive Glover - Senior Global Marketing Manager, Cell & Gene Therapy, Pall Biotech, UK

Recombinant Adeno-Associated virus (rAAV) vectors are promising tools for development of gene therapies, as shown by encouraging clinical results for various diseases and the approval of at least 2 drugs in the last 5 years.

Despite significant advances in the development of suspension cell lines and transfection methods, viral vector batches for clinical trials are still largely produced by scaling-out the laboratory process in static 2D multi-tray stacks (MT). With such an approach, both the compliance to current Good Manufacturing Practice (cGMP) and the manufacturing cost can become a challenge and delay the commercialization of these therapies. Modeling cost of the final manufacturing process as early as possible in the process development, will help select the right manufacturing platform that will deliver a therapy at an acceptable cost for patients.

This study compares the cost for three upstream (USP) methods for producing rAAV using Biosolve software (Biopharm services), a reference tool for cost analysis in the biopharmaceutical industry. The traditional MT-based process is compared to a suspension process and a fixed-bed process based on Pall’s iCELLis® bioreactor system. Clinical scale (200 L) and manufacturing scales (800 L – 1000 L) are considered for each process type and both upstream and downstream (DSP) process are included in the model to give an idea of overall cost of goods (CoGs). Through analysis of the cost break-down for the different manufacturing scenarios, opportunities for cost reduction could be identified. As such it was found that the cost and quantity of clinical grade plasmid DNA (pDNA), the essential reagent for transient transfection, was an important contributor to the overall CoGs. It was also found that the iCELLis bioreactor system offers a cost-efficient alternative for viral vector manufacturing.

15:20 - 15:40 20 mins
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
Agility by Design: a new strategy to address the cell & gene therapy manufacturing challenges
  • Denis Bedoret - Managing Director, MaSTherCell
15:20 - 15:50 30 mins
Info
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
CMC Analytical Tools for IND/IMPD Submissions and Beyond: Assay Validation Requirements
  • Stuart Dunn - Senior Assay Development Manager, Bioassay, BioPharmaceuticals CMC - Large Molecules, Covance
  • Paul Byrne - Lead Scientist, Cell and Gene Therapy – Biopharmaceutical CMC Solutions, Covance, UK

The analytical tools required to support the development of cell and gene therapy molecules cover a range of disciplines, each with different validation requirements. The approaches used should be based on the understanding of the product, its critical quality attributes, safety profile and the proposed mechanism, or mechanisms, of action that relate to clinical effect. This talk will focus on the analytical assays used to bring these therapies to the market, and the phase-appropriate validation that are required. The talk will include a case study for a potency assay for a product in early clinical phase, with details of how the validation was addressed.

15:40 - 16:00 20 mins
Info
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Raw Materials for ATMP Manufacturing: Supply Security
  • Bernd Leistler - Director Development & Production, CellGenix, Germany

Ancillary materials (AM, also termed raw materials) are crucial for the quality, safety and efficacy of a cell or gene therapy product.

The use of fully traceable, GMP manufactured and preferrably animal-derived component-free (ADCF) AM, significantly reduces qualification and validation efforts and helps to ensure consistency, safety and purity of cell & gene therapy medicinal products. With the first approved cell and gene therapy medicines with significant market volume, the need of high quality AM is increasing strongly. Thus the AM suppliers have to be prepared to maintain a high quality standard at significantly larger manufacturing scale.

15:40 - 16:00 20 mins
Info
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
The good, the bad and the process
  • Stefano Baila - Director of Operations & Business Development, Anemocyte, Italy
16:00 - 16:30 30 mins
Afternoon Coffee
16:30 - 17:40 70 mins
Info
Stream 1: Manufacturing and Process Development – Analytical Strategies, Design Space, QbD and Cost of Goods Considerations
Dual Dialogue: When to make the decision to either insource or outsource
  • Lior Raviv - Vice President of Development, Pluristem
  • Greg Stromberg - Associate Director, Global Manufacturing Sciences, Biogen, USA
Dual Dialogue: When to make the decision to either insource or outsource
  • When is the best time to make the decision on in sourcing vs. outsourcing?
  • What are the limitations of building your capabilities in house?
  • What are the benefits vs. the costs?
  • Pros and cons of both models
  • What is better for large vs. small companies?
  • What sort of bioprocess equipment makes sense for CMO’s opposed to therapeutic companies?
  •  Enterprise solutions vs. ability to customise


Gene Therapy Tech Transfer – Navigating PFDs, CMOs, and PPQs.

This presentation will provide an overview of tech transfer process of our current gene therapy programs.  Also, this talk with summarize a focus on partnership and how a strong partnership with research and CMO partners is vital in enabling ability to meet program deliverables and timelines.  Finally, an overview will be provided on how Biogen plans to approach process validation / qualification. 

Greg Stromberg, Associate Director, Biogen

16:30 - 17:40 70 mins
Info
Stream 2: Facility Design, Manufacturing Networks and End to End Solutions for Commercial Success
Dual Dialogue: When to make the decision to either insource or outsource
  • Lior Raviv - Vice President of Development, Pluristem
  • Greg Stromberg - Associate Director, Global Manufacturing Sciences, Biogen, USA
Dual Dialogue: When to make the decision to either insource or outsource
  • When is the best time to make the decision on in sourcing vs. outsourcing?
  • What are the limitations of building your capabilities in house?
  • What are the benefits vs. the costs?
  • Pros and cons of both models
  • What is better for large vs. small companies?
  • What sort of bioprocess equipment makes sense for CMO’s opposed to therapeutic companies?
  •  Enterprise solutions vs. ability to customise


Gene Therapy Tech Transfer – Navigating PFDs, CMOs, and PPQs.

This presentation will provide an overview of tech transfer process of our current gene therapy programs.  Also, this talk with summarize a focus on partnership and how a strong partnership with research and CMO partners is vital in enabling ability to meet program deliverables and timelines.  Finally, an overview will be provided on how Biogen plans to approach process validation / qualification. 

Greg Stromberg, Associate Director, Biogen

16:30 - 17:05 35 mins
Info
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Transforming cell therapy with gene editing: the case of “off-the-shelf” engineered CAR-T in the clinic
  • David Sourdive - Executive Vice President Technical Operations, Cellectis

Gene-editing has enabled off-the-shelf allogeneic CAR-T product candidates to reach the clinic. It is also endowing engineered cells with multiple new features, enhancing their capabilities and functions to better address cancer. Hindsight in industrializing 3 different such gene-edited immuno-oncology products now in active trials, and the human clinical experience with the first cases in ongoing studies signal practical avenues for their further deployment and shed light on the transformative role they will play in the anti-cancer arsenal.

17:05 - 17:40 35 mins
Stream 3: Clinical Development for Cell, Gene and Immunotherapies
Discovery of Novel TcRs for Cancer Therapy
  • Marc van Dijk - Vice President, Platform Technology, AgenTus Therapeutics, Inc.,
17:40 - 17:50 10 mins
Time to move into Plenary Session
17:50 - 18:10 20 mins
Info
Rapid Quantification of Adeno-Associated Virus and Lentivirus Vectors
  • Rebecca Montange - Scientist, Sartorius Stedim North America, Inc, USA

Viral vectors such as adeno-associated virus (AAV) and lentivirus are currently in use for gene and cell therapies.  Rapid and accurate enumeration of these viral particles is critical for the safety and efficacy of these promising new therapies.  However, obtaining this information can be a challenge as current techniques are slow and imprecise.   ELISA tests are subjective and the variability depends on the operator.  qPCR takes hours and ultimately only delivers a genome count.  While vector genomes/mL is required for dosing, further characterization of the vector formulations is required for patient safety.  Furthermore, the amount of time involved in these methods makes them challenging for use in in-process monitoring of vector growth and formulation.  The Virus Counter 3100® platform using antibody-based ViroTag® reagents from Sartorius Virus Analytics offers a rapid and precise solution to these problems. 

Here, we show how the ViroTag AAV2-3 and ViroTag VSV-G can be used to quantify crude and purified AAV-2, AAV-3, and VSV-G pseudo-typed lentivirus vectors.  Using a patented no-wash assay and the Virus Counter 3100 platform, biologically relevant total particle counts can be obtained in three minutes following a 30 minute incubation.   The speed and precision of this technique makes it practical for in-process monitoring as well as characterization of a final formulation.

18:10 - 18:30 20 mins
Info
Gene Therapy Center Austria: High quality AAV solutions for clinical and commercial supply.
  • Larissa Kahr - Head of Gene Therapy Strategy & Business Development Process Development & Technical Services, Shire, Austria

FDA expects to approve 40 gene therapies by 2022, a significant number is based on AAV. As of today PhI/II AAV capacities are installed at product companies and CMOs but no set-ups are available to support industries GT ambitions.

The Gene Therapy Center Austria (GTCA) proprietary AAV platform covers all steps from vector to product including a broad range of analytical methods. 40+ GMP lots have already been released out of our state-of-the-art Gene Therapy plant specifically designed for AAV processes, demonstrating lot-to-lot consistency and process robustness across AAV subtypes. Our partners benefit from our 30+ years’ experience in late stage development and global commercialization of recombinant proteins and vaccines.

18:30 - 20:30 120 mins
Networking Drinks and Evening Social Event